1. A pharmaceutical composition comprising an open matrix network containing a pharmaceutically active ingredient, wherein the open matrix network contains Levan. A pharmaceutical composition comprising a matrix containing a pharmaceutically active ingredient, wherein the matrix rapidly disintegrates upon contact with an aqueous medium or saliva, and wherein said matrix contains levan. 3. The pharmaceutical composition according to claim 1 or 2, where Levan is the main matrix-forming agent. The pharmaceutical composition according to claim 1 or 2, wherein the matrix contains levan and mannitol. The pharmaceutical composition according to claim 1 or 2, wherein the matrix contains levan and trehalose. The pharmaceutical composition according to claim 1 or 2, wherein the matrix contains levan and raffinose. The pharmaceutical composition according to claim 1 or 2, wherein at least 80% of said composition is dissolved in an aqueous medium or saliva within 30 seconds. The pharmaceutical composition of claim 7, wherein at least 80% of said composition is dissolved in an aqueous medium or saliva within 10 seconds. The pharmaceutical composition according to claim 1 or 2, having a tensile strength of about 0.05-1.6 N / mmi high dissolution rate, such that at least 80% of the composition dissolves in an aqueous medium or saliva within 30 seconds. The pharmaceutical composition of claim 9, wherein the composition dissolves in an aqueous medium or saliva within 10 seconds. The pharmaceutical composition according to claim 1 or 2 in an oral dosage form. The pharmaceutical composition according to claim 11, adapted for sublingual administration. The pharmaceutical composition according to claim 1 or 2, obtained by sublimation of the solvent from a liquid preparation containing the active ingredient and Levan in1. Фармацевтическая композиция, содержащая открытую матричную сеть, несущую фармацевтически активный ингредиент, где открытая матричная сеть содержит леван.2. Фармацевтиче
